Phage cocktails and the future of phage therapy

Future Microbiology

Volumn 8, Issue 6, 2013, Pages 769-783

  Chan, Benjamin K ^a   Abedon, Stephen T ^b   Loc Carrillo, Catherine ^a,c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

antibacterial; antibiotic resistance; bacteriophage; diversity of bacterial pathogen; phage cocktail; polyphage

Indexed keywords

ANTIINFECTIVE AGENT; INFLUENZA VACCINE;

BACTERIAL INFECTION; BACTERIOPHAGE; BACTERIOPHAGE TYPING; CAMPYLOBACTER JEJUNI; CLOSTRIDIUM PERFRINGENS; DOMESTIC ANIMAL; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; HUMAN; KLEBSIELLA PNEUMONIAE; LISTERIA MONOCYTOGENES; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SALMONELLA ENTERITIDIS; SALMONELLA TYPHIMURIUM; STAPHYLOCOCCUS PHAGE; VIBRIO CHOLERAE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BACTERIOPHAGES; BIOLOGICAL THERAPY; DRUG APPROVAL; HUMANS;

ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 84878321621     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.13.47     Document Type: Review

References (106)

1. Matsuzaki S, Rashel M, Uchiyama J, et al. Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J. Infect. Chemother. 11(5), 211-219 (2005 (Pubitemid 41570015)
2. Fischbach MA, Walsh CT. Antibiotics for emerging pathogens. Science 325(5944), 1089-1093 (2009
3. Relman DA. The human microbiome: ecosystem resilience and health. Nutr. Rev. 70(Suppl. 1), S2-S9 (2012
4. Rea MC, Dobson A, O'Sullivan O, et al. Effect of broad-and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc. Natl Acad. Sci. USA 108(Suppl. 1), 4639-4644 (2011
5. Hyman P, Abedon ST. Bacteriophage host range and bacterial resistance. Adv. Appl. Microbiol. 70, 217-248 (2010
6. Twort FW. An investigation on the nature of ultra-microscopic viruses. Lancet 189, 1241-1243 (1915
7. D'Hérelle F. On an invisible microbe antagonistic to dysentery bacilli. C.R. Acad. Sci. Paris 165, 373-375 (1917
8. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage 1(2), 66-85 (2011
9. Kutter E, De Vos D, Gvasalia G, et al. Phage therapy in clinical practice: treatment of human infections. Curr. Pharm. Biotechnol. 11(1), 69-86 (2010
10. Miedzybrodzki R, Borysowski J, Weber-Dabrowska B, et al. Clinical aspects of phage therapy. Adv. Virus Res. 83, 73-121 (2012
11. Skurnik M, Pajunen M, Kiljunen S. Biotechnological challenges of phage therapy. Biotechnol. Lett. 29(7), 995-1003 (2007 (Pubitemid 46800624)
12. Gill JJ, Hyman P. Phage choice, isolation and preparation for phage therapy. Curr. Pharm. Biotechnol. 11(1), 2-14 (2010
13. Brussow H. What is needed for phage therapy to become a reality in western medicine? Virology 434(2), 138-142 (2012
14. Chanishvili N. A Literature Review of the Practical Application of Bacteriophage Research. Chanishvili N (Ed.). Nova Science Publishers, NY, USA (2012
15. Carlton RM. Phage therapy: past history and future prospects. Arch. Immunol. Ther. Exp. (Warsz) 47(5), 267-274 (1999
16. Skurnik M, Strauch E. Phage therapy: facts and fiction. Int. J. Med. Microbiol. 296(1), 5-14 (2006 (Pubitemid 43089713)
17. Hendrix RW, Smith MCM, Burns RN, Ford ME, Hatfull GF. Evolutionary relationships among diverse bacteriophages and prophages: all the world's a phage. Proc. Natl Acad. Sci. USA 96(5), 2192-2197 (1999 (Pubitemid 29117890)
18. Balogh B, Jones JB, Iriarte FB, Momol MT. Phage therapy for plant disease control. Curr. Pharm. Biotechnol. 11(1), 48-57 (2010
19. Wagemans J, Lavigne R. Phages and their hosts, a web of interactions -applications to drug design. In: Bacteriophages in Health and Disease. Hyman P, Abedon ST (Eds). CABI Press, UK, 119-133 (2012
20. Curtright AJ, Abedon ST. Phage therapy: emergent property pharmacology. J. Bioanal. Biomed. S6, 002 (2011
21. Abedon S. Phage therapy pharmacology: calculating phage dosing. Adv. Appl. Microbiol. 77, 1-40 (2011
22. Abedon ST. Bacteriophages as drugs: the pharmacology of phage therapy. In: Phage Therapy: Current Research and Applications. Borysowski J, Miêdzybrodzki R, Górski A (Eds). Caister Academic Press, UK (2013) (In press
23. Abedon ST. Bacteriophages and Biofilms: Ecology, Phage Therapy, Plaques. Nova Science Publishers, NY, USA (2011
24. Abedon ST, Thomas-Abedon C. Phage therapy pharmacology. Curr. Pharm. Biotechnol. 11(1), 28-47 (2010
25. Cairns BJ, Timms AR, Jansen VA, Connerton IF, Payne RJ. Quantitative models of in vitro bacteriophage-host dynamics and their application to phage therapy. PLoS Pathog. 5(1), e1000253 (2009
26. Chan BK, Abedon ST. Bacteriophage adaptation, with particular attention to issues of phage host range. In: Bacteriophages in Dairy Processing. Quiberoni A, Reinheimer J (Eds). Nova Science Publishers, NY, USA, 25-52 (2012
27. Goodridge LD. Designing phage therapeutics. Curr. Pharm. Biotechnol. 11(1), 15-27 (2010
28. Chan BK, Abedon ST. Phage therapy pharmacology: phage cocktails. Adv. Appl. Microbiol. 78, 1-23 (2012
29. Gorski A, Miedzybrodzki R, Borysowski J, et al. Phage as a modulator of immune responses: practical implications for phage therapy. Adv. Virus Res. 83, 41-71 (2012
30. Abedon ST. Phage therapy best practices. In: Bacteriophages in Health and Disease. Hyman P, Abedon ST (Eds). CABI Press, UK, 256-272 (2012
31. Hall AR, De VD, Friman VP, Pirnay JP, Buckling A. Effects of sequential and simultaneous application of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in waxmoth larvae. Appl. Environ. Microbiol. 78(16), 5646-5652 (2012
32. Levin BR, Bull JJ. Population and evolutionary dynamics of phage therapy. Nat. Rev. Microbiol. 2(2), 166-173 (2004 (Pubitemid 39490070)
33. Soni KA, Nannapaneni R, Hagens S. Reduction of Listeria monocytogenes on the surface of fresh channel catfish fillets by bacteriophage Listex P100. Foodborne Pathog. Dis. 7(4), 427-434 (2010
34. Maura D, Galtier M, Le BC, Debarbieux L. Virulent bacteriophages can target O104:H4 enteroaggregative Escherichia coli in the mouse intestine. Antimicrob. Agents Chemother. 56(12), 6235-6242 (2012
35. Bull JJ, Otto G, Molineux IJ. In vivo growth rates are poorly correlated with phage therapy success in a mouse infection model. Antimicrob. Agents Chemother. 56(2), 949-954 (2012
36. Loc Carrillo C, Atterbury RJ, El Shibiny A, et al. Bacteriophage therapy to reduce Campylobacter jejuni colonization of broiler chickens. Appl. Environ. Microbiol. 71(11), 6554-6563 (2005 (Pubitemid 43194136)
37. Abedon ST. Kinetics of phage-mediated biocontrol of bacteria. Foodborne Pathog. Dis. 6(7), 807-815 (2009
38. Carlton RM. Phage therapy: past history and future prospects. Arch. Immunol. Ther. Exp. 47(5), 267-274 (1999
39. Viazis S, Akhtar M, Feirtag J, Diez-Gonzalez F. Reduction of Escherichia coli O157:H7 viability on leafy green vegetables by treatment with a bacteriophage mixture and trans-cinnamaldehyde. Food Microbiol. 28(1), 149-157 (2011
40. Gu J, Liu X, Li Y, et al. A method for generation phage cocktail with great therapeutic potential. PLoS ONE 7(3), e31698 (2012
41. Jaiswal A, Koley H, Ghosh A, Palit A, Sarkar B. Efficacy of cocktail phage therapy in treating Vibrio cholerae infection in rabbit model. Microbes Infect. 15(2), 152-156 (2012
42. Oliveira A, Sereno R, Azeredo J. In vivo efficiency evaluation of a phage cocktail in controlling severe colibacillosis in confined conditions and experimental poultry houses. Vet. Microbiol. 146(3-4), 303-308 (2010
43. McVay CS, Velasquez M, Fralick JA. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob. Agents Chemother. 51(6), 1934-1938 (2007 (Pubitemid 46903076)
44. Wright A, Hawkins CH, Anggård EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryng. 34(4), 349-357 (2009
45. Abedon ST. Lysis and the interaction between free phages and infected cells. In: The Molecular Biology of Bacteriophage T4. Karam JD, Kutter E, Carlson K, Guttman B (Eds). ASM Press, Washington, DC, USA, 397-405 (1994
46. Kelly D, McAuliffe O, Ross RP, O'Mahony J, Coffey A. Development of a broad-host-range phage cocktail for biocontrol. Bioeng. Bugs 2(1), 31-37 (2011
47. sLabrie SJ, Samson JE, Moineau S. Bacteriophage resistance mechanisms. Nat. Rev. Microbiol. 8(5), 317-327 (2010
48. Filippov AA, Sergueev KV, He Y, et al. Bacteriophage-resistant mutants in Yersinia pestis: identification of phage receptors and attenuation for mice. PLoS ONE 6(9), e25486 (2011
49. Verbeken G, Pirnay JP, De Vos D, et al. Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine. Arch. Immunol. Ther. Exp.(Warsz.) 60(3), 161-172 (2012
50. Loc-Carrillo C, Abedon ST. Pros and cons of phage therapy. Bacteriophage 1(2), 111-114 (2011
51. Loc-Carrillo C, Wu S, Beck JP. Phage therapy of wounds and related purulent infections. In: Bacteriophages in Health and Disease. Hyman P, Abedon ST (Eds). CABI Press, UK, 185-202 (2012
52. Olszowska-Zaremba N, Borysowski J, Dabrowska J, Górski A. Phage translocation, safety, and immunomodulation. In: Bacteriophages in Health and Disease. Hyman P, Abedon ST (Eds). CABI Press, UK, 168-184 (2012
53. Devasahayam G, Scheld WM, Hoffman PS. Newer antibacterial drugs for a new century. Expert. Opin. Investig. Drugs 19(2), 215-234 (2010
54. Williams ML, LeJeune JT. Phages and bacterial epidemiology. In: Bacteriophages in Health and Disease. Hyman P, Abedon ST (Eds). CABI Press, UK, 76-85 (2012
55. van Rooij T, Wilson DM, Marsh S. Personalized medicine policy challenges: measuring clinical utility at point of care. Expert. Rev. Pharmacoecon. Outcomes Res. 12(3), 289-295 (2012
56. Pirnay JP, De Vos D, Verbeken G, et al. The phage therapy paradigm: prêt-à-porter or sur-mesure? Pharm. Res. 28(4), 934-937 (2011
57. Burrowes B, Harper DR. Phage therapy of nonwound infections. In: Bacteriophages in Health and Disease. Hyman P, Abedon ST (Eds). CABI Press, UK, 203-216 (2012
58. Zhang X, Wei D, Yap Y, et al. Mass spectrometry-based 'omics' technologies in cancer diagnostics. Mass Spectrom. Rev. 26(3), 403-431 (2007 (Pubitemid 46750377)
59. Manolio TA, Green ED. Genomics reaches the clinic: from basic discoveries to clinical impact. Cell 147(1), 14-16 (2011
60. Gosalbes MJ, Abellan JJ, Durban A, et al. Metagenomics of human microbiome: beyond 16s rDNA. Clin. Microbiol. Infect. 18(Suppl. 4), 47-49 (2012
61. Brambilla F, Lavatelli F, Merlini G, Mauri P. Clinical proteomics for diagnosis and typing of systemic amyloidoses. Proteomics Clin. Appl. 7(1-2), 136-143 (2013
62. Yang N, Ginsburg GS, Simmons LA. Personalized medicine in women's obesity prevention and treatment: implications for research, policy and practice. Obes. Rev. 14(2), 145-161 (2013
63. Cox CR. Bacteriophage-based methods of bacterial detection and identification. In: Bacteriophages in Health and Disease. Hyman P, Abedon ST (Eds). CABI Press, UK, 134-152 (2012
64. Thiel K. Old dogma, new tricks -21st century phage therapy. Nat. Biotech. 22(1), 31-36 (2004 (Pubitemid 38057949)
65. Keen EC. Phage therapy: concept to cure. Front. Mirobiol. 3, 238 (2012
66. Nichol KL, Treanor JJ. Vaccines for seasonal and pandemic influenza. J. Infect. Dis. 194(Suppl. 2), S111-S118 (2006 (Pubitemid 44630954)
67. Couch RB. Seasonal inactivated influenza virus vaccines. Vaccine 26(Suppl. 4), D5-D9 (2008
68. Christie GE, Allison HA, Kuzio J, et al. Prophage-induced changes in cellular cytochemistry and virulence. In: Bacteriophages in Health and Disease. Hyman P, Abedon ST (Eds). CABI Press, UK, 33-60 (2012
69. Kuhl S, Hyman P, Abedon ST. Diseases caused by phages. In: Bacteriophages in Health and Disease. Hyman P, Abedon ST (Eds). CABI Press, UK, 21-32 (2012
70. Bradshaw J, Wright PF. Cold-adapted influenza vaccines. Curr. Opin. Pediatr. 14(1), 95-98 (2002 (Pubitemid 34169577)
71. Pouillot F, Blois H, Iris F. Genetically engineered virulent phage banks in the detection and control of emergent pathogenic bacteria. Biosecur. Bioterror. 8(2), 155-169 (2010
72. Gomez Lorenzo MM, Fenton MJ. Immunobiology of influenza vaccines. Chest 143(2), 502-510 (2013
73. Finch R. Regulatory opportunities to encourage technology solutions to antibacterial drug resistance. J. Antimicrob. Chemother. 66(9), 1945-1947 (2011
74. Wood JM, Levandowski RA. The influenza vaccine licensing process. Vaccine 21(16), 1786-1788 (2003 (Pubitemid 36398374)
75. Harper DR. Biological control by microorganisms. In: The Encyclopedia of Life Sciences. John Wiley & Sons, UK, 1-10 (2006
76. Kesselheim AS, Outterson K. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals. Health Aff. (Millwood) 29(9), 1689-1696 (2010
77. Sommer MO, Dantas G. Antibiotics and the resistant microbiome. Curr. Opin. Microbiol. 14(5), 556-563 (2011
78. Miller RW, Skinner EJ, Sulakvelidze A, Mathis GF, Hofacre CL. Bacteriophage therapy for control of necrotic enteritis of broiler chickens experimentally infected with Clostridium perfringens. Avian Dis. 54(1), 33-40 (2010
79. Abuladze T, Li M, Menetrez MY, et al. Bacteriophages reduce experimental contamination of hard surfaces, tomato, spinach, broccoli, and ground beef by Escherichia coli O157:H7. Appl. Environ. Microbiol. 74(20), 6230-6238 (2008
80. Merabishvili M, Pirnay J-P, Verbeken G, et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS ONE 4(3), e4944 (2009
81. Fu W, Forster T, Mayer O, et al. Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system. Antimicrob. Agents Chemother. 54(1), 397-404 (2010
82. Kunisaki H, Tanji Y. Intercrossing of phage genomes in a phage cocktail and stable coexistence with Escherichia coli O157:H7 in anaerobic continuous culture. Appl. Microbiol. Biotechnol. 85(5), 1533-1540 (2010
83. Born Y, Fieseler L, Marazzi J, et al. Novel virulent and broad-host-range Erwinia amylovora bacteriophages reveal a high degree of mosaicism and a relationship to Enterobacteriaceae phages. Appl. Environ. Microbiol. 77(17), 5945-5954 (2011
84. Viazis S, Akhtar M, Feirtag J, Diez-Gonzalez F. Reduction of Escherichia coli O157:H7 viability on hard surfaces by treatment with a bacteriophage mixture. Int. J. Food Microbiol. 145(1), 37-42 (2011
85. Bach SJ, Johnson RP, Stanford K, McAllister TA. Bacteriophages reduce Escherichia coli O157:H7 levels in experimentally inoculated sheep. Can. J. Anim. Sci. 89, 285-293 (2009
86. Kumari S, Harjai K, Chhibber S. Efficacy of bacteriophage treatment in murine burn wound infection induced by Klebsiella pneumoniae. J. Microbiol. Biotechnol. 19(6), 622-628 (2009
87. Carvalho CM, Gannon BW, Halfhide DE, et al. The in vivo efficacy of two administration routes of a phage cocktail to reduce numbers of Campylobacter coli and Campylobacter jejuni in chickens. BMC Microbiol. 10, 232 (2010
88. Wall SK, Zhang J, Rostagno MH, Ebner PD. Phage therapy to reduce preprocessing Salmonella infections in market-weight swine. Appl. Environ. Microbiol. 76(1), 48-53 (2010
89. Alemayehu D, Casey PG, McAuliffe O, et al. Bacteriophages αMR299-2 and βNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio 3(2), e00029-12 (2012
90. Anany H, Chen W, Pelton R, Griffiths MW. Biocontrol of Listeria monocytogenes and Escherichia coli O157:H7 in meat byusing phages immobilized on modified cellulose membranes. Appl. Environ. Microbiol. 77(18), 6379-6387 (2011
91. Hooton SP, Atterbury RJ, Connerton IF. Application of a bacteriophage cocktail to reduce Salmonella Typhimurium U288 contamination on pig skin. Int. J. Food Microbiol. 151(2), 157-163 (2011
92. McLean S, Dunn L, Palombo E. Bacteriophage biocontrol has the potential to reduce enterococci on hospital fabrics, plastic and glass. World J. Microbiol. Biotechnol. 27, 1713-1717 (2011
93. Hawkins C, Harper D, Burch D, Anggard E, Soothill J. Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: a before/after clinical trial. Vet. Microbiol. 145(3-4), 309-313 (2010
94. Rivas L, Coffey B, McAuliffe O, et al. In vivo and ex vivo evaluations of bacteriophages e11/2 and e4/1c for use in the control of Escherichia coli O157:H7. Appl. Environ. Microbiol. 76(21), 7210-7216 (2010
95. Denou E, Bruttin A, Barretto C, et al. T4 phages against Escherichia coli diarrhea: potential and problems. Virology 388(1), 21-30 (2009
96. Kumari S, Harjai K, Chhibber S. Bacteriophage treatment of burn wound infection caused by Pseudomonas aeruginosa PAO in BALB/c mice. Am. J. Biomed. Sci. 1(4), 385-394 (2009
97. Rozema EA, Stephens TP, Bach SJ, et al. Oral and rectal administration of bacteriophages for control of Escherichia coli O157:H7 in feedlot cattle. J. Food Prot. 72(2), 241-250 (2009
98. Borie C, Albala I, Sanchez P, et al. Bacteriophage treatment reduces Salmonella colonization of infected chickens. Avian Dis. 52(1), 64-67 (2008 (Pubitemid 351497483)
99. Filho RLA, Higgins JP, Higgins SE, et al. Ability of bacteriophages isolated from different sources to reduce Salmonella enterica serovar Enteritidis in vitro and in vivo. Poult. Sci. 86(9), 1904-1909 (2007 (Pubitemid 47580895)
100. Bebbington C, Yarranton G. Antibodies for the treatment of bacterial infections: current experience and future prospects. Curr. Opin. Biotechnol. 19(6), 613-619 (2008
101. Fischetti VA. Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens. Int. J. Med. Microbiol. 300(6), 357-362 (2010
102. Cotter PD, Ross RP, Hill C. Bacteriocins -a viable alternative to antibiotics? Nat. Rev. Microbiol. 11(2), 95-105 (2013
103. Submission of GRAS notification of bacteriophage P100. www.accessdata.fda.gov/scripts/fcn/gras-notices/612853A.PDF
104. Federal Register, Volume 71, Issue 160 (2006). www.gpo.gov/fdsys/pkg/FR- 2006-08-18/html/E6-13621.htm
105. The Code of Federal Regulations (CFR), title 21, volume 7, subpart E. Accelerated approval of biological products for serious or life-threatening illnesses. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm? CFRPart=601&showF R=1&subpartNode=21:7.0.1.1.2.5
106. US Environmental Protection Agency. What are biopesticides? www.epa.gov/opp00001/biopesticides/whatarebiopesticides.htm